Medium materiality6/10
Edgewise Therapeutics price target raised to $59 from $48 at RBC Capital
Why it may matterVerify against the original reporting
Target upgrade implies strong upside potential; price remains well below target.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Target raised to $59; Posted price $34.51; RBC Capital
- Target raised to $59; Price $34.51; RBC Capital
Key facts
- 01
Target: $59
- 02
Posted price: $34.51
- 03
Analyst firm: RBC Capital
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.